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also evaluated.
Results: The study was stopped early due to the superiority
of CT. Ninety percent of patients in the CT group did not
experienced OM, compared to 36% and 34% in the Caphosolâ
and SS groups, respectively (P < 0.0001). None of the CT
patients experienced grade 3-4 OM. There was a signiﬁcant
decrement in duration of OM in the CT group compared to
the Caphosolâ group (mean duration [MD] in days 0.8 vs.
4.77; p < 0.001) and the SS group (MD 5.55 days; p < 0.001).
Duration of OMwas shorter in the CT group compared to the
SS group (MD .9 days vs. 3.38 days; p ¼ 0.004) and the
Caphosolâ group (MD 2.97 days; p¼ 0.020). Patients in the CT
group required less use of analgesics when compared with
the SS group (p ¼ 0.007).
Conclusion: CT signiﬁcantly reduces OM incidence, severity
and duration. . Patients who received CT had lower analgesic
requirements than patients who received SS.310
Amphotericin B Nasal Spray Appears Effective in
Preventing Breakthrough Fungal Infections in Colonized
SCT Recipients
Steven Triﬁlio 1, Ryan Heraty 1, Athanasios Zomas 1, Derek Liu 1,
Junyu Zhang 1, Cindy Zhao 1, Jayesh Mehta 2. 1 NorthwesternNumber of colonized patients(%) 109(5.6)
Total Isolates 117
Autologous 78(5.7)
Allogeneic (MDS) 14(5.4)
Allogeneic (MUD) 17(5)
Yeast (Non-speciated) 57
Alternaria 20
Penicillium 12
Aspergillus spp 11
Molds (Non-spp) 8
Cladosporium 3
Fusarium 2
Others 6
History of prior IFI 8
Change in systemic antifungal therapy 25
Eradication of nasal colonization(%) 100
Documented breakthrough IFI 1Memorial Hospital, Chicago, IL; 2 Hematology/Oncology,
Northwestern University Feinberg School of Medicine,
Chicago, IL
Fungal colonization may increase the risk for developing
invasive fungal infections(IFI) for patients undergoing stem
cell transplants (SCT). At Northwestern Memorial Hospital a
protocol was initiated in 2005 to administer amphotericin B
decanoate nasal spray to all SCT recipients with fungal nasal
colonization.
Amphotericin B 0.5% nasal spray was given twice daily in
addition to systemic prophylaxis (ﬂuconazole for auto-SCT’s
or voriconazole 200 mg for allo-SCT’s) to all patients with
nasal fungal colonization. Nasal surveillance cultures were
repeated within 7- 30 days of Ampho B initiation. An inde-
pendent expert reviewer was utilized to determine the
presence of IFI according to EORTC criteria.
Amongst1936patients reviewed,117 fungal isolates (62mould
and57yeast )were identiﬁed fromthenaresof109patients (78
auto/31allo). Therewasnosigniﬁcantdifference inage, gender,
diagnosis, transplant or donor type betweenpatientswith and
without nasal fungal colonization. Eight patients had a prior
history of IFI. Nasal surveillance cultures after Ampho B began
showed 100% eradication of all isolates. One breakthrough IFI
was observed amongst the 109 Ampho B treated patients
(Alternia ssp.soft tissue infection in auto-SCT successfully
treated with voriconazole). Systemic Antifungal prophylaxis
waschanged in25patients, primarily for febrileneutropeniaor
liver enzyme abnormalities. Nasal Ampho Bwaswell tolerated
and no patient discontinued use during transplantation.
Intranasal Ampho B effectively eradicates nasal fungal colo-
nization and appears effective in preventing breakthrough
fungal infections in colonized HSCT recipients.311
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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S206Background: Probiotic supplementation has been promoted
for a variety of health conditions. Increased marketing and
over-the-counter (OTC) access in pharmacies, health food
stores and grocery chains has also led to increased avail-
ability of these agents. Since safety of probiotic supplemen-
tation within the hematopoietic cell transplant (HCT)
population is unknown, we sought to evaluate the incidence
and outcomes of bacteremia due to organisms common to
many of these OTC probiotic supplements in a population of
HCT recipients.
Methods: We reviewed all blood culture results from a
cohort of HCT recipients transplanted at Fred Hutchinson
Cancer Research Center in Seattle, WA between 2002-2011.
Patients with at least one positive blood culture for
common probiotic organisms (Lactobacillus species, Biﬁdo-
bacterium species, or Streptococcus thermophilus) within
one-year post-HCT were considered cases for this study.
Patients with evidence of preexisting bacteremia from
these agents (3 months prior to HCT) were excluded. Data
were collected from center databases, which contain
archived laboratory data, patient demographics, and clin-
ical summaries.
Results: A total of 18/3799 (0.47%) HCT recipients developed
bacteremia with Lactobacillus species within one-year post-
HCT; no events with Biﬁdobacterium species or S. thermo-
philus were identiﬁed. Patients who developed these events
had a median age of 49 years (IQR: 41, 53), and the majority
were allogeneic transplant recipients (n¼13, 72%). Most
patients had a singular positive blood culture (n¼17 [94%]);
one patient developed prolonged bacteremia (30 days).
Positive blood cultures for Lactobacillus species occurred at
a median of 84 days post-transplant (IQR: 34, 127), with
most (n¼12 [67%]) occurring within the ﬁrst 100-days. The
overall incidence rate of Lactobacillus bacteremia was 1.54
cases per 100,000 patient-days; the highest incidence
occurred during the ﬁrst 100-days post-transplant (3.31
cases per 100,000 patient-days). Incidence did not deviate
signiﬁcantly by year of transplant. At the time of diagnosis,
most HCT recipients were inpatient (n¼12 [67%]) for a
median of 37 days (IQR: 6, 78) prior to development of
bacteremia. Among outpatients (6/18 [30%]), four were
admitted within 30 days after their ﬁrst positive culture.Eight patients (44%) were diagnosed with acute graft-
versus-host disease of the gut prior to the development of
bacteremia. No Lactobacillus-attributed mortality was
observed during follow-up.
Conclusion: Organisms frequently incorporated in available
OTC probiotic supplements are infrequent causes of bacter-
emia after HCT. Studies evaluating the use of probiotics
among these high-risk patients are needed.312
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Bronchiolitis obliterans syndrome (BOS) is associated with
signiﬁcant morbidity and mortality following allogeneic
stem cell transplant (SCT). Deﬁned by NIH consensus
criteria, the diagnosis is often confounded by the presence
of concurrent infectious complications in affected patients,
making interpretation of spirometry and imaging studies
difﬁcult. We now report a novel imaging biomarker
that identiﬁes obstructive small airway disease, even in
the presence of infectious pneumonitis. A computed to-
mography (CT)-based image processing technique termed
parametric response mapping (PRM) has been generated
at our center to capture parenchymal alterations conse-
quent to lung disease. PRM is performed from a biphasic
(inspiratory and expiratory) high-resolution-CT (HRCT),
with subsequent image co-registration of the paired HRCT
data, and classiﬁcation of individual voxels within the lung
parenchyma as either (a) normal, (b) severe emphysema-
tous disease, (b) functional small airway disease (fSAD)
